BLK vs ZBIO · P/E 27, rev $24.22B vs rev $10.0M
BlackRock Inc (BLK) versus Zenas BioPharma, Inc. Common Stock (ZBIO) — a side-by-side from cached financials, not a winner call.
BlackRock Inc (BLK) is a asset management company listed on NYSE. It is led by Larry Fink.
Zenas BioPharma, Inc. Common Stock (ZBIO) is a biotechnology company listed on US.
Latest reported BLK revenue for 2025-12-31 was $24.22B. Net income was $5.55B. Revenue was up 89.3% from 2024-12-31 to 2025-12-31. BLK currently screens at market cap $172.19B and trailing P/E 26.6.
Latest reported ZBIO revenue for 2025-12-31 was $10.0M. Net income was -$377.7M. Revenue was up 100.0% from 2024-12-31 to 2025-12-31. ZBIO currently screens at market cap $798.0M.
BLK currently screens at market cap $172.19B and trailing P/E 26.6. ZBIO currently screens at market cap $798.0M.
Not investment advice. Open the BLK and ZBIO stock pages for the full models.
Not investment advice.